Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fatty liver after pancreatic cancer surgery linked to worse outcomes

NCT ID NCT07182136

Knowledge-focused Sponsor: Wei-Hsun Lu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at 200 patients with early-stage pancreatic cancer who had Whipple surgery. Researchers found that some patients developed fatty liver within six months after surgery, which may affect nutrition, blood sugar control, and long-term survival. The goal is to help doctors and patients understand these risks and improve follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict and manage fatty liver after Whipple surgery, potentially improving survival and quality of life for pancreatic cancer patients.
What could go wrong
This is a completed retrospective study, not a treatment trial. It can show links but cannot prove cause and effect. Results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Jan 2015

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Two hundred patients with stage I-II pancreatic ductal adenocarcinoma who underwent pancreaticoduodenectomy between 2015 and 2023 at two Taiwanese tertiary centers were included; those with preoperative fatty liver, incomplete data, or early death were excluded

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults with stage I-II pancreatic ductal adenocarcinoma. * Underwent curative-intent pancreaticoduodenectomy (conventional or pylorus-preserving). * Surgery between January 2015 and May 2023. * Complete clinical and imaging data available. * Survived at least 6 months postoperatively. Exclusion Criteria: * Preoperative hepatic steatosis * Incomplete clinical or imaging data * Death within 6 months after surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonalcoholic fatty liver disease after pancreaticoduodenectomy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatotic liver disease pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonalcoholic fatty liver disease after pancreaticoduodenectomy

More trials for these conditions

Other studies related to the condition(s) this trial covers.